136 related articles for article (PubMed ID: 37751825)
21. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells
Brauneck F; Oliveira-Ferrer L; Muschhammer J; Sturmheit T; Ackermann C; Haag F; Schulze Zur Wiesch J; Ding Y; Qi M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Wellbrock J
Front Immunol; 2023; 14():1250258. PubMed ID: 37876933
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages.
Kim SH; Saeidi S; Zhong X; Gwak SY; Muna IA; Park SA; Kim SH; Na HK; Joe Y; Chung HT; Kim KE; Han W; Surh YJ
Neoplasia; 2020 Nov; 22(11):606-616. PubMed ID: 33039895
[TBL] [Abstract][Full Text] [Related]
23. Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy.
Zhou Y; Guo Y; Chen L; Zhang X; Wu W; Yang Z; Li X; Wang Y; Hu Z; Wang Z
Theranostics; 2022; 12(12):5488-5503. PubMed ID: 35910792
[No Abstract] [Full Text] [Related]
24. Efferocytosis: a double-edged sword in microbial immunity.
Mohammad-Rafiei F; Moadab F; Mahmoudi A; Navashenaq JG; Gheibihayat SM
Arch Microbiol; 2023 Nov; 205(12):370. PubMed ID: 37925389
[TBL] [Abstract][Full Text] [Related]
25. Efferocytosis in the tumor microenvironment.
Werfel TA; Cook RS
Semin Immunopathol; 2018 Nov; 40(6):545-554. PubMed ID: 30187085
[TBL] [Abstract][Full Text] [Related]
26. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
[TBL] [Abstract][Full Text] [Related]
27. Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro.
Lecoultre M; Chliate S; Espinoza FI; Tankov S; Dutoit V; Walker PR
Radiother Oncol; 2024 Jan; 190():110049. PubMed ID: 38072365
[TBL] [Abstract][Full Text] [Related]
28. In situ injectable nano-complexed hydrogel based on chitosan/dextran for combining tumor therapy via hypoxia alleviation and TAMs polarity regulation.
Zhang W; Shi Y; Li H; Yu M; Zhao J; Chen H; Kong M
Carbohydr Polym; 2022 Jul; 288():119418. PubMed ID: 35450661
[TBL] [Abstract][Full Text] [Related]
29. Targeting tumor-associated macrophages for cancer immunotherapy.
Cao X; Lai SWT; Chen S; Wang S; Feng M
Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD47 antibody synergizes with cisplatin against laryngeal cancer by enhancing phagocytic ability of macrophages.
Wang J; Zhang H; Yin X; Bian Y
Clin Exp Immunol; 2021 Sep; 205(3):333-342. PubMed ID: 33999416
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Efferocytosis Assays.
Evans AL; Blackburn JW; Yin C; Heit B
Methods Mol Biol; 2017; 1519():25-41. PubMed ID: 27815871
[TBL] [Abstract][Full Text] [Related]
32. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy.
Yang A; Sheng S; Bai Y; Xing G; Yu X; Zhu D; Mei L; Dong X; Lv F
Acta Biomater; 2022 Nov; 153():124-138. PubMed ID: 36179979
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors.
Liu Y; Xue R; Duan X; Shang X; Wang M; Wang F; Zhu L; Zhang L; Ge X; Zhao X; Guo H; Wang Z; Zhang L; Gao X; Shen A; Sheng Y; Qin Z
Life Sci; 2023 Aug; 326():121790. PubMed ID: 37211345
[TBL] [Abstract][Full Text] [Related]
34. Chimeric Peptide Engineered Bioregulator for Metastatic Tumor Immunotherapy through Macrophage Polarization and Phagocytosis Restoration.
Chen XY; Yan MY; Liu Q; Yu BX; Cen Y; Li SY
ACS Nano; 2023 Aug; 17(16):16056-16068. PubMed ID: 37578051
[TBL] [Abstract][Full Text] [Related]
35. Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy.
Zhang YR; Luo JQ; Zhang JY; Miao WM; Wu JS; Huang H; Tong QS; Shen S; Leong KW; Du JZ; Wang J
Small; 2020 Nov; 16(46):e2004240. PubMed ID: 33107142
[TBL] [Abstract][Full Text] [Related]
36. Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages.
Ahirwar DK; Charan M; Mishra S; Verma AK; Shilo K; Ramaswamy B; Ganju RK
Cancer Res; 2021 Oct; 81(20):5255-5267. PubMed ID: 34400395
[TBL] [Abstract][Full Text] [Related]
37. Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma.
Wang F; Huang Q; Su H; Sun M; Wang Z; Chen Z; Zheng M; Chakroun RW; Monroe MK; Chen D; Wang Z; Gorelick N; Serra R; Wang H; Guan Y; Suk JS; Tyler B; Brem H; Hanes J; Cui H
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2204621120. PubMed ID: 37098055
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.
Zhang M; Hutter G; Kahn SA; Azad TD; Gholamin S; Xu CY; Liu J; Achrol AS; Richard C; Sommerkamp P; Schoen MK; McCracken MN; Majeti R; Weissman I; Mitra SS; Cheshier SH
PLoS One; 2016; 11(4):e0153550. PubMed ID: 27092773
[TBL] [Abstract][Full Text] [Related]
39. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
[TBL] [Abstract][Full Text] [Related]
40. Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms.
Tajbakhsh A; Rezaee M; Kovanen PT; Sahebkar A
Pharmacol Ther; 2018 Aug; 188():12-25. PubMed ID: 29444453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
